Compare BZFD & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZFD | CELU |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 34.5M |
| IPO Year | N/A | N/A |
| Metric | BZFD | CELU |
|---|---|---|
| Price | $0.82 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 214.1K | 31.7K |
| Earning Date | 03-12-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $184,927,000.00 | $40,578,000.00 |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | $289.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $1.00 |
| 52 Week High | $2.68 | $4.35 |
| Indicator | BZFD | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 44.78 |
| Support Level | $0.78 | $1.20 |
| Resistance Level | $0.89 | $1.31 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 22.62 | 41.75 |
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.